Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
4.900
-0.040 (-0.81%)
Mar 28, 2024, 11:17 AM EDT - Market open
Revance Therapeutics Market Cap
Revance Therapeutics has a market cap or net worth of $514.83 million as of March 28, 2024. Its market cap has decreased by -81.04% in one year.
Market Cap
514.83M
Enterprise Value
738.80M
1-Year Change
-81.04%
Ranking
Category
Stock Price
$4.90
Market Cap Chart
Since February 6, 2014, Revance Therapeutics's market cap has increased from $453.20M to $514.83M, an increase of 13.60%. That is a compound annual growth rate of 1.27%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 27, 2024 | 435.80M | 5.11% |
Mar 26, 2024 | 414.60M | 1.07% |
Mar 25, 2024 | 410.20M | -4.52% |
Mar 22, 2024 | 429.60M | -6.16% |
Mar 21, 2024 | 457.80M | 2.37% |
Mar 20, 2024 | 447.20M | 2.83% |
Mar 19, 2024 | 434.90M | -0.21% |
Mar 18, 2024 | 435.80M | -6.88% |
Mar 15, 2024 | 468.00M | -2.30% |
Mar 14, 2024 | 479.00M | -9.79% |
Mar 13, 2024 | 531.00M | -4.22% |
Mar 12, 2024 | 554.40M | 0.40% |
Mar 11, 2024 | 552.20M | 4.15% |
Mar 8, 2024 | 530.20M | -2.43% |
Mar 7, 2024 | 543.40M | -2.84% |
Mar 6, 2024 | 559.30M | -2.46% |
Mar 5, 2024 | 573.40M | 7.08% |
Mar 4, 2024 | 535.50M | -13.03% |
Mar 1, 2024 | 615.70M | -2.24% |
Feb 29, 2024 | 629.80M | 26.14% |
Feb 28, 2024 | 499.30M | -0.24% |
Feb 27, 2024 | 500.50M | 0.16% |
Feb 26, 2024 | 499.70M | 3.65% |
Feb 23, 2024 | 482.10M | 3.39% |
Feb 22, 2024 | 466.30M | -1.12% |
View and export this data all the way back to 2014.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
CareDx | 495.52M |
Replimune Group | 494.17M |
IGM Biosciences | 493.81M |
Lyell Immunopharma | 487.86M |
Esperion Therapeutics | 484.84M |
MultiPlan | 482.44M |
Marinus Pharmaceuticals | 481.40M |
Alto Neuroscience | 480.71M |